Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Marinus Pharmaceuticals

< Previous 1 2 3 4 Next >
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.